IMPLANET Reports Full-Year 2025 Revenue of €12.5 Million, Up Sharply by +33%

About this update from Implanet Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1749,"height":653,"url":"https://media.zenfs.com/en/business-wire.com/462585bff15b49682ca0410ddb31eac7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/loRPpXC8jDC4wCM5eeNTWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/462585bff15b49682ca0410ddb31eac7","width":960,"height":358},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eQq4HGLO51j7fpIZkqZALw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/462585bff15b49682ca0410ddb31eac7","width":1200,"height":448}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. sales +49% in 2025 (+56% at constant exchange rates)","length":57,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":57,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"First deliveries of JAZZ® to China following CFDA approval, totaling €0.5 million","length":81,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":81,"olType":false},{"type":"text","content":"BORDEAUX, France & BOSTON, January 13, 2026--(BUSINESS WIRE)--Regulatory News:","length":82,"tagName":"p"},{"type":"text","content":"IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announces its full-year 2025 revenue as well as its cash position as of December 31, 2025.","length":296,"tagName":"p"},{"type":"text","content":"Ludovic Lastennet, CEO of IMPLANET, stated: "We delivered a very strong commercial performance in 2025, with revenue of €12.5 million, representing +33% growth compared with the same period last year, thereby confirming the relevance of the development model we have been implementing for the past two years. Building on six consecutive quarters of sustained growth, we are firmly confident in the outlook for the coming quarters. The strong momentum in implant sales, up +36% in the fourth quarter, has been driven by the continued opening of new accounts in the French market, the expansion into new export countries, and the first JAZZ surgeries performed in ...

More updates from Implanet Sa